Evidence map›Paper›PMID 38008488›Full record

ArticleJournal of cancer policy2023

A tailored approach to horizon scanning for cancer medicines.

Jennifer A Soon, Yat Hang To, Marliese Alexander, Karen Trapani, Paolo A Ascierto, Sophy Athan, Michael P Brown, Matthew Burge, Andrew Haydon, Brett Hughes and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer policy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Jennifer A SoonCentre for Health Policy, Cancer Health Services Research, University of Melbourne, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. Electronic address: Jennifer.Soon@unimelb.edu.au.
Yat Hang ToGibbs Laboratory, Walter and Eliza Hall Institute of Research, Parkville, Australia.
Marliese AlexanderSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Australia.
Karen TrapaniCentre for Health Policy, Cancer Health Services Research, University of Melbourne, Melbourne, Australia.
Paolo A AsciertoIstituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
Sophy AthanVictorian Comprehensive Cancer Centre Alliance, Melbourne, Australia.
Michael P BrownCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, Australia; School of Medicine, The University of Adelaide, Adelaide, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia.
Matthew BurgeDepartment of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, Australia; Department of Medical Oncology, Prince Charles Hospital, Chermside, Australia.
Andrew HaydonDepartment of Medical Oncology, Alfred Health, Melbourne, Australia; Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia.
Brett HughesDepartment of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, Australia; Department of Medical Oncology, Prince Charles Hospital, Chermside, Australia; The University of Queensland, Brisbane, Australia.
Malinda ItchinsDepartment of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia; Northern Clinical School, The University of Sydney, St Leonards, Australia.
Thomas JohnSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Steven KaoDepartment of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, Australia; School of Medicine, The University of Sydney, Sydney, Australia.
Miriam KoopmanMedical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
Bob T LiMemorial Sloan Kettering Cancer Centre and Weill Cornell Medicine, New York, USA.
Georgina V LongSchool of Medicine, The University of Sydney, Sydney, Australia; Melanoma Institute Australia, Sydney, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia.
Jonathan M LoreeDivision of Medical Oncology, BC Cancer, Vancouver, Canada.
Ben MarkmanDepartment of Medical Oncology, Alfred Health, Melbourne, Australia; Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia.
Tarek M MeniawySir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia.
Alexander M MenziesSchool of Medicine, The University of Sydney, Sydney, Australia; Melanoma Institute Australia, Sydney, Australia.
Louise NottRoyal Hobart Hospital, Hobart, Australia; Icon Cancer Centre, Hobart, Australia.
Nick PavlakisDepartment of Medical Oncology, Royal North Shore Hospital, St Leonards, Australia; School of Medicine, The University of Sydney, Sydney, Australia.
Teresa M PetrellaSunnybrook Odette Cancer Centre, Toronto, Canada.
Sanjay PopatLung Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies, The Institute of Cancer Research, London, UK.
Jeanne TieSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Gibbs Laboratory, Walter and Eliza Hall Institute of Research, Parkville, Australia.
Wen XuPrincess Alexandra Hospital, Brisbane, Australia; University of Queensland, Brisbane, Australia.
Desmond YipDepartment of Medical Oncology, The Canberra Hospital, Garran, Australia; School of Medicine and Psychology, Australian National University, Canberra, Australia.
John ZalcbergDepartment of Medical Oncology, Alfred Health, Melbourne, Australia; Erasmus School of Health Policy and Management, Rotterdam, the Netherlands.
Benjamin J SolomonSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Peter GibbsGibbs Laboratory, Walter and Eliza Hall Institute of Research, Parkville, Australia.
Grant A McArthurSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Victorian Comprehensive Cancer Centre Alliance, Melbourne, Australia.
Fanny FranchiniCentre for Health Policy, Cancer Health Services Research, University of Melbourne, Melbourne, Australia.
Maarten IJzermanErasmus School of Health Policy and Management, Rotterdam, the Netherlands.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
HER2-mediated delivery of cytotoxic agents in solid tumorsR01CA249666 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT · 2021 to 2024
$2.3M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA249666
6 · The paper itself

Abstract

backgroundHorizon scanning (HS) is the systematic identification of emerging therapies to inform policy and decision-makers. We developed an agile and tailored HS methodology that combined multi-criteria decision analysis weighting and Delphi rounds. As secondary objectives, we aimed to identify new medicines in melanoma, non-small cell lung cancer and colorectal cancer most likely to impact the Australian government's pharmaceutical budget by 2025 and to compare clinician and consumer priorities in cancer medicine reimbursement.

methodThree cancer-specific clinician panels (total n = 27) and a consumer panel (n = 7) were formed. Six prioritisation criteria were developed with consumer input. Criteria weightings were elicited using the Analytic Hierarchy Process (AHP). Candidate medicines were identified and filtered from a primary database and validated against secondary and tertiary sources. Clinician panels participated in a three-round Delphi survey to identify and score the top five medicines in each cancer type.

resultsThe AHP and Delphi process was completed in eight weeks. Prioritisation criteria focused on toxicity, quality of life (QoL), cost savings, strength of evidence, survival, and unmet need. In both curative and non-curative settings, consumers prioritised toxicity and QoL over survival gains, whereas clinicians prioritised survival. HS results project the ongoing prevalence of high-cost medicines. Since completion in October 2021, the HS has identified 70 % of relevant medicines submitted for Pharmaceutical Benefit Advisory Committee assessment and 60% of the medicines that received a positive recommendation.

conclusionTested in the Australian context, our method appears to be an efficient and flexible approach to HS that can be tailored to address specific disease types by using elicited weights to prioritise according to incremental value from both a consumer and clinical perspective. POLICY SUMMARY: Since HS is of global interest, our example provides a reproducible blueprint for adaptation to other healthcare settings that integrates consumer input and priorities.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAustraliaEvidence-Based MedicineHumansPharmaceutical PreparationsQuality of LifePharmaceutical PreparationsBiomedicalCancerColorectal cancerCommunity involvementDecision makingHealth care costsHealth policyHealth prioritiesMelanomaNon-small cell lung cancerTechnology assessment

Identifiers

PMID38008488
PMCPMC11272392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.